Sökning: id:"swepub:oai:DiVA.org:uu-124875" >
Dasatinib induces r...
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib : interim results of a phase 2 study
-
Ottmann, Oliver (författare)
-
Dombret, Hervé (författare)
-
Martinelli, Giovanni (författare)
-
visa fler...
-
- Simonsson, Bengt (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Blodsjukdomar
-
Guilhot, Francois (författare)
-
Larson, Richard A. (författare)
-
Rege-Cambrin, Giovanna (författare)
-
Radich, Jerald (författare)
-
Hochhaus, Andreas (författare)
-
Apanovitch, Anne Marie (författare)
-
Gollerkeri, Ashwin (författare)
-
Coutre, Steven (författare)
-
visa färre...
-
(creator_code:org_t)
- American Society of Hematology, 2007
- 2007
- Engelska.
-
Ingår i: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 110:7, s. 2309-2315
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Patients with Philadelphia (Ph) chromosome-positive acute lymphoblastic leukemia (ALL) have a rapid disease course and a poor prognosis. Dasatinib, a novel, oral, multitargeted kinase inhibitor of BCR-ABL and SRC family kinases, has previously induced responses in patients with imatinib-resistant or -intolerant Ph-positive ALL. We present the interim results of a phase 2 study designed to further assess the efficacy, safety, and tolerability of dasatinib 140 mg in this patient population (n = 36). With a minimum follow-up of 8 months, treatment with dasatinib resulted in substantial hematologic and cytogenetic response rates. Major hematologic responses were achieved in 42% (15/36) of patients, 67% of whom remained progression-free. Complete cytogenetic responses were attained by 58% (21/36) of patients. The presence of BCR-ABL mutations conferring imatinib resistance did not preclude a response to dasatinib. Dasatinib was also tolerable, with 6% (2/36) of patients discontinuing therapy as a result of study-drug toxicity. Most adverse events (AEs) were grade 1 or 2; febrile neutropenia was the most frequent severe AE, but this and other cytopenias were manageable with dose reduction. Dasatinib represents a safe and effective treatment option and an important therapeutic advance for patients with Ph-positive ALL. This trial was registered at www.clinicaltrials.gov as #CA180015.
Nyckelord
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
Blood
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Ottmann, Oliver
-
Dombret, Hervé
-
Martinelli, Giov ...
-
Simonsson, Bengt
-
Guilhot, Francoi ...
-
Larson, Richard ...
-
visa fler...
-
Rege-Cambrin, Gi ...
-
Radich, Jerald
-
Hochhaus, Andrea ...
-
Apanovitch, Anne ...
-
Gollerkeri, Ashw ...
-
Coutre, Steven
-
visa färre...
- Artiklar i publikationen
-
Blood
- Av lärosätet
-
Uppsala universitet